NYSE:NUVBPharmaceuticals
Nuvation Bio (NUVB) Stock Rises On IBTROZI Growth And Deeper Losses
Nuvation Bio stock jumped about 8% to US$6.60 after its Q2 earnings, a sharp move for a small oncology player that investors largely treat as a long haul drug platform story. The headline this quarter is not a surprise profit. It is the pressure on the income statement as the company leans into commercial and research spending, with a Q2 net loss of US$62.8m on US$31.7m of revenue.
For you as a shareholder, the question now is whether that widening loss is tolerable in exchange for the...